Browse > Article
http://dx.doi.org/10.5125/jkaoms.2018.44.5.220

Metachronous second primary malignancy in head and neck cancer patients: is five years of follow-up sufficient?  

Adeel, Mohammad (Department of Surgical Oncology, Section of Head and Neck Oncology, Shaukat Khanum Memorial Cancer Hospital)
Siddiqi, Moghira Iqbal (Department of Otolaryngology & Head and Neck Surgery, The Aga Khan University Hospital)
Publication Information
Journal of the Korean Association of Oral and Maxillofacial Surgeons / v.44, no.5, 2018 , pp. 220-224 More about this Journal
Abstract
Objectives: The aim of this study was to determine the incidence and characteristics of second primary malignancy (SPM) in patients with head and neck squamous cell carcinoma treated at a tertiary care hospital. Materials and Methods: We retrospectively reviewed the medical records of 221 patients who underwent surgery with or without adjuvant treatment for head and neck cancer from 2000 to 2002. Data of age, sex, risk factors, sites of primary and SPM, TNM stage of primary tumor, incidence of SPM, and survival were collected from medical charts. Results: Eighteen patients developed SPM during a median follow-up of 67 months, with an overall incidence of 8.14%. In addition, 77.7% of SPMs occurred in the oral cavity, followed by 11% in the lungs. The 5-year overall survival after the diagnosis of SPM in the head or neck was 70%, compared to 30% for SPM in other body regions. Conclusion: Considering a high incidence of SPM, i.e., 8.14%, in a mean follow-up period of 67 months suggests the need for long-term follow-up. Since treatment of SPM has shown an acceptable survival rate, early detection and curative therapy should be emphasized.
Keywords
Second primary malignancy; Survivorship; Survival rate;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Chu PY, Chang SY, Huang JL, Tai SK. Different patterns of second primary malignancy in patients with squamous cell carcinoma of larynx and hypopharynx. Am J Otolaryngol 2010;31:168-74.   DOI
2 Fujisawa R, Shibuya H, Harata N, Yuasa-Nakagawa K, Toda K, Hayashi K. Chronological shifts and changing causes of death after radiotherapy for early-stage oral cancer. Int J Clin Oncol 2014;19:24-9.   DOI
3 Schwartz LH, Ozsahin M, Zhang GN, Touboul E, De Vataire F, Andolenko P, et al. Synchronous and metachronous head and neck carcinomas. Cancer 1994;74:1933-8.   DOI
4 Cooper JS, Pajak TF, Rubin P, Tupchong L, Brady LW, Leibel SA, et al. Second malignancies in patients who have head and neck cancer: incidence, effect on survival and implications based on the RTOG experience. Int J Radiat Oncol Biol Phys 1989;17:449-56.   DOI
5 Lippman SM, Hong WK. Second malignant tumors in head and neck squamous cell carcinoma: the overshadowing threat for patients with early-stage disease. Int J Radiat Oncol Biol Phys 1989;17:691-4.   DOI
6 Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010;17:1471-4.   DOI
7 Vikram B, Strong EW, Shah JP, Spiro R. Second malignant neoplasms in patients successfully treated with multimodality treatment for advanced head and neck cancer. Head Neck Surg 1984;6:734-7.   DOI
8 Warren S. Multiple primary malignant tumors: a survey of the literature and statistical study. Am J Cancer 1932;16:1358-414.
9 Hong WK, Lippman SM, Itri LM, Karp DD, Lee JS, Byers RM, et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 1990;323:795-801.   DOI
10 Leon X, del Prado Venegas M, Orus C, Kolanczak K, Garcia J, Quer M. Metachronous second primary tumours in the aerodigestive tract in patients with early stage head and neck squamous cell carcinomas. Eur Arch Otorhinolaryngol 2005;262:905-9.   DOI
11 Leon X, Ferlito A, Myer CM 3rd, Saffiotti U, Shaha AR, Bradley PJ, et al. Second primary tumors in head and neck cancer patients. Acta Otolaryngol 2002;122:765-78.   DOI
12 Leon X, Quer M, Orus C, del Prado Venegas M, Lopez M. Distant metastases in head and neck cancer patients who achieved locoregional control. Head Neck 2000;22:680-6.   DOI
13 Ecimovic P, Pompe-Kirn V. Second primary cancers in laryngeal cancer patients in Slovenia, 1961-1996. Eur J Cancer 2002;38:1254-60.   DOI
14 Dikshit RP, Boffetta P, Bouchardy C, Merletti F, Crosignani P, Cuchi T, et al. Risk factors for the development of second primary tumors among men after laryngeal and hypopharyngeal carcinoma. Cancer 2005;103:2326-33.   DOI
15 Mehdi I, Shah AH, Moona MS, Verma K, Abussa A, Elramih R, et al. Synchronous and metachronous maligant tumours expect the unexpected. J Pak Med Assoc 2010;60:905-9.
16 Hong WK, Bromer RH, Amato DA, Shapshay S, Vincent M, Vaughan C, et al. Patterns of relapse in locally advanced head and neck cancer patients who achieved complete remission after combined modality therapy. Cancer 1985;56:1242-5.   DOI
17 Sturgis EM, Miller RH. Second primary malignancies in the head and neck cancer patient. Ann Otol Rhinol Laryngol 1995;104:946- 54.   DOI
18 Chen JY, Chang YL, Yu YC, Chao CC, Kao HW, Wu CT, et al. Specific induction of the high-molecular-weight microtubule-associated protein 2 (hmw-MAP2) by betel quid extract in cultured oral keratinocytes: clinical implications in betel quid-associated oral squamous cell carcinoma (OSCC). Carcinogenesis 2004;25:269- 76.
19 Hsu YB, Chang SY, Lan MC, Huang JL, Tai SK, Chu PY. Second primary malignancies in squamous cell carcinomas of the tongue and larynx: an analysis of incidence, pattern, and outcome. J Chin Med Assoc 2008;71:86-91.   DOI
20 Di Martino E, Sellhaus B, Hausmann R, Minkenberg R, Lohmann M, Esthofen MW. Survival in second primary malignancies of patients with head and neck cancer. J Laryngol Otol 2002;116:831-8.
21 Leon X, Quer M, Diez S, Orus C, Lopez-Pousa A, Burgues J. Second neoplasm in patients with head and neck cancer. Head Neck 1999;21:204-10.   DOI